US Patent

US9649352 — High purity oritavancin and method of producing same

Formulation · Assigned to Medicines Co · Expires 2035-07-16 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects high purity oritavancin drug substance preparations and pharmaceutical compositions used in drug products or dosage forms.

USPTO Abstract

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Drugs covered by this patent

oritavancin-diphosphate (ORITAVANCIN DIPHOSPHATE)

Patent Metadata

Patent number: US9649352
Jurisdiction: US
Classification: Formulation
Expires: 2035-07-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Medicines Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.